AnaptysBio Inc. (ANAB)

Business: AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

IPO Date: 26-Jan-2017

Interim Pres & CEO and Director: Mr. Daniel R. Faga

COO & Gen. Counsel: Mr. Eric J. Loumeau

Listing: NASDAQ: ANAB

Country: United States

Headquarters: San Diego, CA

Website: https://www.anaptysbio.com

Market cap: $589.09 Mln

Revenue (TTM): $52.90 Mln

Earnings (TTM): $-75.89 Mln

Cash: $505.62 Mln

Total Debt: $20.60 Mln

Insider's Holding: 0.35%

Liquidity: Low

52 Week range: $18.20 - 37.89

Shares outstanding: 28,186,100

9 Years Aggregate:

• CFO: $-207.43 Mln
• EBITDA: $-267.31 Mln
• Net Profit: $-278.47 Mln